MDT

100.95

+0.14%↑

138.9

-0.46%↓

VEEV

224.25

+1.77%↑

HQY

87.03

+1.99%↑

NEOG

9.94

+0.91%↑

MDT

100.95

+0.14%↑

138.9

-0.46%↓

VEEV

224.25

+1.77%↑

HQY

87.03

+1.99%↑

NEOG

9.94

+0.91%↑

MDT

100.95

+0.14%↑

138.9

-0.46%↓

VEEV

224.25

+1.77%↑

HQY

87.03

+1.99%↑

NEOG

9.94

+0.91%↑

MDT

100.95

+0.14%↑

138.9

-0.46%↓

VEEV

224.25

+1.77%↑

HQY

87.03

+1.99%↑

NEOG

9.94

+0.91%↑

MDT

100.95

+0.14%↑

138.9

-0.46%↓

VEEV

224.25

+1.77%↑

HQY

87.03

+1.99%↑

NEOG

9.94

+0.91%↑

Начало・Списък с акции・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

42.05 2.56

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

40.13

Максимум

42.63

Ключови измерители
By Trading Economics
Приходи	-6.2M -91M
Марж на печалбата	-867.293
Служители	316
EBITDA	4M -90M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+30.37% upside

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-141M 3.1B
Предишно отваряне	39.49
Предишно затваряне	42.05

Настроения в новините

By Acuity

34%

66%

111 / 360 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

34.81 / 38.24 Подкрепа & съпротива

Xenon Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.01.2026 г., 23:49 ч. UTC

Значими двигатели на пазара

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21.01.2026 г., 21:12 ч. UTC

Значими двигатели на пазара

Automaker Stocks Rise After Trump Calls Off European Tariffs

21.01.2026 г., 21:00 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21.01.2026 г., 20:29 ч. UTC

Значими двигатели на пазара

Chip Makers Gain After Trump Calls Off European Tariffs

21.01.2026 г., 20:04 ч. UTC

Значими двигатели на пазара

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21.01.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21.01.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21.01.2026 г., 22:39 ч. UTC

Печалби

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

21.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

21.01.2026 г., 21:35 ч. UTC

Придобивния, сливания и поглъщания

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21.01.2026 г., 21:19 ч. UTC

Печалби

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21.01.2026 г., 20:45 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Borse Group to Acquire Allfunds for $6.19B

21.01.2026 г., 20:36 ч. UTC

Пазарно говорене

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21.01.2026 г., 20:31 ч. UTC

Пазарно говорене

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21.01.2026 г., 20:27 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21.01.2026 г., 20:27 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

21.01.2026 г., 20:27 ч. UTC

Пазарно говорене

Was It a 'TACO' Event? -- Market Talk

21.01.2026 г., 20:26 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21.01.2026 г., 20:23 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21.01.2026 г., 20:21 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21.01.2026 г., 20:19 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse Group Agrees to Buy Allfunds

21.01.2026 г., 20:08 ч. UTC

Печалби

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21.01.2026 г., 20:03 ч. UTC

Пазарно говорене

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21.01.2026 г., 19:51 ч. UTC

Пазарно говорене

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21.01.2026 г., 19:43 ч. UTC

Пазарно говорене

U.S. Ethanol Production Expected to Slip -- Market Talk

21.01.2026 г., 19:31 ч. UTC

Пазарно говорене

Gold Settles at Fresh All-Time High -- Market Talk

21.01.2026 г., 19:24 ч. UTC

Печалби

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21.01.2026 г., 19:10 ч. UTC

Пазарно говорене

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21.01.2026 г., 18:57 ч. UTC

Пазарно говорене

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Xenon Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

30.37% нагоре

12-месечна прогноза

Среден 54.09 USD 30.37%

Висок 62 USD

Нисък 44 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Xenon Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Xenon Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

34.81 / 38.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

111 / 360 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.